These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 18457612)
21. Osteoarthritis: a review of treatment options. Seed SM; Dunican KC; Lynch AM Geriatrics; 2009 Oct; 64(10):20-9. PubMed ID: 20726384 [TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470 [TBL] [Abstract][Full Text] [Related]
23. Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management. Shah S; Mehta V Postgrad Med J; 2012 Feb; 88(1036):73-8. PubMed ID: 22052884 [TBL] [Abstract][Full Text] [Related]
24. The role of analgesics in the management of osteoarthritis pain. Brandt KD Am J Ther; 2000 Mar; 7(2):75-90. PubMed ID: 11319576 [TBL] [Abstract][Full Text] [Related]
25. Current state of therapy for pain and inflammation. Abramson SB; Weaver AL Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S1-6. PubMed ID: 16168076 [TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Rannou F; Pelletier JP; Martel-Pelletier J Semin Arthritis Rheum; 2016 Feb; 45(4 Suppl):S18-21. PubMed ID: 26806189 [TBL] [Abstract][Full Text] [Related]
28. Practical considerations for the pharmacologic management of osteoarthritis. Altman RD Am J Manag Care; 2009 Sep; 15(8 Suppl):S236-43. PubMed ID: 19817510 [TBL] [Abstract][Full Text] [Related]
29. Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly. Huang WN; Tso TK Bosn J Basic Med Sci; 2018 Feb; 18(1):87-94. PubMed ID: 28954205 [TBL] [Abstract][Full Text] [Related]
30. Complexities in the pharmacologic management of osteoarthritis pain. McCarberg B; Tenzer P Curr Med Res Opin; 2013 May; 29(5):539-48. PubMed ID: 23489409 [TBL] [Abstract][Full Text] [Related]
31. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672 [TBL] [Abstract][Full Text] [Related]
32. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Price-Forbes AN; Callaghan R; Allen ME; Rowe IF Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035 [TBL] [Abstract][Full Text] [Related]